Headlines about OpGen (NASDAQ:OPGN) have trended somewhat positive on Tuesday, according to Accern. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. OpGen earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned news headlines about the medical research company an impact score of 46.6930012217366 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

These are some of the headlines that may have effected Accern’s rankings:

A number of equities analysts have weighed in on OPGN shares. HC Wainwright set a $1.00 target price on shares of OpGen and gave the company a “buy” rating in a research note on Tuesday, July 18th. Zacks Investment Research raised shares of OpGen from a “sell” rating to a “hold” rating in a research note on Wednesday, June 28th. Finally, Dawson James reaffirmed a “buy” rating on shares of OpGen in a research note on Monday, June 19th.

OpGen (NASDAQ OPGN) opened at 0.2583 on Tuesday. OpGen has a 52 week low of $0.24 and a 52 week high of $3.10. The firm’s 50 day moving average is $0.41 and its 200-day moving average is $0.81. The company’s market cap is $13.32 million.

In other OpGen news, Chairman Jven Capital, Llc purchased 1,875,000 shares of the stock in a transaction dated Tuesday, July 18th. The stock was purchased at an average price of $0.40 per share, with a total value of $750,000.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Timothy C. Dec purchased 65,000 shares of the stock in a transaction dated Tuesday, July 18th. The stock was acquired at an average cost of $0.40 per share, with a total value of $26,000.00. Following the transaction, the chief financial officer now directly owns 118,966 shares in the company, valued at approximately $47,586.40. The disclosure for this purchase can be found here. 53.27% of the stock is currently owned by corporate insiders.

WARNING: This article was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this article on another site, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The legal version of this article can be read at https://www.watchlistnews.com/opgen-opgn-earns-daily-news-impact-rating-of-0-17/1489952.html.

About OpGen

OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.

Insider Buying and Selling by Quarter for OpGen (NASDAQ:OPGN)

Receive News & Ratings for OpGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.